The Apex Times
Above the Noise
Business Wire
BusinessGoldman Sachs and JPMorgan Chase both raise dividends, prompting fresh debate over which large bank offers the better valueThe Apex TimesBusinessNike stock’s sharp underperformance is drawing fresh bullish arguments, but details remain thinThe Apex TimesBusinessModerna’s Phase 3 cancer vaccine win and Nasdaq-100 inclusion highlight shift toward oncologyThe Apex TimesBusinessLeidos (LDOS) wins $56 million Naval Health Research Center award and extends UK defence logistics workThe Apex TimesBusinessDefense Stocks Watch: RTX Adds Counter-Drone Business as AeroVironment Announces International Deals and Palantir Moves With New AI VentureThe Apex TimesBusinessNavy C-130J-30 Delivery Points to Continued Progress for Lockheed’s TACAMO Mission, Investors Watch for Follow-ThroughThe Apex TimesBusinessMastercard pushes a stablecoin-ready payments “switchboard,” aiming to make crypto rails easier for banksThe Apex TimesBusinessLockheed Martin’s missile backlog and new PAC-3 Edge interceptor add momentum as investors weigh valuationThe Apex TimesBusinessEli Lilly investors who bought in 2025 focused on what the company implied, even as the stock outpaced the broader marketThe Apex TimesBusinessTSMC warns AI chip demand still outpaces supply, reigniting focus on Nvidia’s role in the buildoutThe Apex TimesBusinessBlackRock Investors Weigh How Private Markets and Active ETFs Could Change Fee StreamsThe Apex TimesBusinessMag 7 roundup spotlights Tesla Roadster timeline, Nvidia’s “space AI” push and Microsoft’s Nadella security warningThe Apex TimesBusinessGoldman Sachs and JPMorgan Chase both raise dividends, prompting fresh debate over which large bank offers the better valueThe Apex TimesBusinessNike stock’s sharp underperformance is drawing fresh bullish arguments, but details remain thinThe Apex TimesBusinessModerna’s Phase 3 cancer vaccine win and Nasdaq-100 inclusion highlight shift toward oncologyThe Apex TimesBusinessLeidos (LDOS) wins $56 million Naval Health Research Center award and extends UK defence logistics workThe Apex TimesBusinessDefense Stocks Watch: RTX Adds Counter-Drone Business as AeroVironment Announces International Deals and Palantir Moves With New AI VentureThe Apex TimesBusinessNavy C-130J-30 Delivery Points to Continued Progress for Lockheed’s TACAMO Mission, Investors Watch for Follow-ThroughThe Apex TimesBusinessMastercard pushes a stablecoin-ready payments “switchboard,” aiming to make crypto rails easier for banksThe Apex TimesBusinessLockheed Martin’s missile backlog and new PAC-3 Edge interceptor add momentum as investors weigh valuationThe Apex TimesBusinessEli Lilly investors who bought in 2025 focused on what the company implied, even as the stock outpaced the broader marketThe Apex TimesBusinessTSMC warns AI chip demand still outpaces supply, reigniting focus on Nvidia’s role in the buildoutThe Apex TimesBusinessBlackRock Investors Weigh How Private Markets and Active ETFs Could Change Fee StreamsThe Apex TimesBusinessMag 7 roundup spotlights Tesla Roadster timeline, Nvidia’s “space AI” push and Microsoft’s Nadella security warningThe Apex TimesBusinessGoldman Sachs and JPMorgan Chase both raise dividends, prompting fresh debate over which large bank offers the better valueThe Apex TimesBusinessNike stock’s sharp underperformance is drawing fresh bullish arguments, but details remain thinThe Apex TimesBusinessModerna’s Phase 3 cancer vaccine win and Nasdaq-100 inclusion highlight shift toward oncologyThe Apex TimesBusinessLeidos (LDOS) wins $56 million Naval Health Research Center award and extends UK defence logistics workThe Apex TimesBusinessDefense Stocks Watch: RTX Adds Counter-Drone Business as AeroVironment Announces International Deals and Palantir Moves With New AI VentureThe Apex TimesBusinessNavy C-130J-30 Delivery Points to Continued Progress for Lockheed’s TACAMO Mission, Investors Watch for Follow-ThroughThe Apex TimesBusinessMastercard pushes a stablecoin-ready payments “switchboard,” aiming to make crypto rails easier for banksThe Apex TimesBusinessLockheed Martin’s missile backlog and new PAC-3 Edge interceptor add momentum as investors weigh valuationThe Apex TimesBusinessEli Lilly investors who bought in 2025 focused on what the company implied, even as the stock outpaced the broader marketThe Apex TimesBusinessTSMC warns AI chip demand still outpaces supply, reigniting focus on Nvidia’s role in the buildoutThe Apex TimesBusinessBlackRock Investors Weigh How Private Markets and Active ETFs Could Change Fee StreamsThe Apex TimesBusinessMag 7 roundup spotlights Tesla Roadster timeline, Nvidia’s “space AI” push and Microsoft’s Nadella security warningThe Apex TimesBusinessGoldman Sachs and JPMorgan Chase both raise dividends, prompting fresh debate over which large bank offers the better valueThe Apex TimesBusinessNike stock’s sharp underperformance is drawing fresh bullish arguments, but details remain thinThe Apex TimesBusinessModerna’s Phase 3 cancer vaccine win and Nasdaq-100 inclusion highlight shift toward oncologyThe Apex TimesBusinessLeidos (LDOS) wins $56 million Naval Health Research Center award and extends UK defence logistics workThe Apex TimesBusinessDefense Stocks Watch: RTX Adds Counter-Drone Business as AeroVironment Announces International Deals and Palantir Moves With New AI VentureThe Apex TimesBusinessNavy C-130J-30 Delivery Points to Continued Progress for Lockheed’s TACAMO Mission, Investors Watch for Follow-ThroughThe Apex TimesBusinessMastercard pushes a stablecoin-ready payments “switchboard,” aiming to make crypto rails easier for banksThe Apex TimesBusinessLockheed Martin’s missile backlog and new PAC-3 Edge interceptor add momentum as investors weigh valuationThe Apex TimesBusinessEli Lilly investors who bought in 2025 focused on what the company implied, even as the stock outpaced the broader marketThe Apex TimesBusinessTSMC warns AI chip demand still outpaces supply, reigniting focus on Nvidia’s role in the buildoutThe Apex TimesBusinessBlackRock Investors Weigh How Private Markets and Active ETFs Could Change Fee StreamsThe Apex TimesBusinessMag 7 roundup spotlights Tesla Roadster timeline, Nvidia’s “space AI” push and Microsoft’s Nadella security warningThe Apex Times
Back to front
Moderna shares surge more than 100% after report of a positive Phase 3 cancer vaccine result
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 19, 10:56 AM EDT

Moderna shares surge more than 100% after report of a positive Phase 3 cancer vaccine result

The jump follows market coverage claiming Moderna’s mRNA cancer vaccine, in collaboration with Merck, posted the first-ever positive Phase 3 outcome for the program.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Moderna’s stock surged sharply on Aug. 19, with market commentary describing a move of more than 100% after news coverage that the company’s mRNA cancer vaccine recorded a positive result in Phase 3, the late-stage clinical trial phase that typically precedes regulatory review.

The report, carried by Yahoo Finance and redistributed through another outlet, specifically tied the alleged Phase 3 success to Moderna’s collaboration with Merck, stating that the program achieved what was characterized as the first-ever positive Phase 3 result for this vaccine approach.

The market reaction underscored how investors treat clinical milestones in biotechnology. When a late-stage trial shows a positive outcome, it can shift expectations for revenue timing, regulatory prospects, and competitive positioning. In contrast, Phase 3 results are often pivotal because they carry the greatest weight for eventual submissions to regulators.

While the price action was dramatic, the publicly shared account summarized the development largely at a headline level. Based on the available material, Moderna and its partners did not provide additional trial details, such as the primary endpoint, magnitude of benefit, or safety findings, within the excerpted report text.

The program’s structure also matters to investors. An mRNA cancer vaccine uses messenger RNA, a genetic instruction delivered to the body so immune cells can recognize targets associated with cancer. Phase 3 trials for these therapies are closely watched because they help determine whether the immune response translates into clinically meaningful outcomes.

Moderna has repeatedly positioned mRNA platforms as a way to produce tailored treatments. For oncology, that means testing vaccine candidates designed to elicit immune activity against cancer-associated targets, and then evaluating whether that activity improves patient outcomes compared with controls in larger populations.

In the current coverage, there is no confirmation of the trial’s size, the patient population, the study design, or the duration of follow-up. Those omissions matter because Phase 3 success can vary widely in how robust the benefit is, and whether results hold across subgroups and endpoints.

Next, investors will typically look for the primary disclosure route that carries the full data package, such as a company press release, a regulatory filing, or a presentation that includes endpoint results and safety summaries. Until those materials are available, the market reaction may outpace what can be independently verified from the headline account alone.

Why It Matters

  • A late-stage oncology result can materially change expectations for regulatory timing and commercial potential.
  • Investor attention to Phase 3 milestones tends to be high for mRNA vaccine platforms, where outcomes can determine whether candidates move toward approvals.
  • Collaboration structure matters, since partnering with a larger pharma company can affect trial execution and future commercialization strategy.
  • Because the available material is headline-level, the market may need primary data disclosures to validate what is being priced in.

Sources

Key Facts

  • Moderna’s shares rose more than 100% on Aug. 19 following market coverage of a positive Phase 3 result.
  • The coverage attributes the reported Phase 3 success to Moderna’s mRNA cancer vaccine program.
  • The report links the outcome to a collaboration with Merck.
  • The post describes the Phase 3 outcome as the first-ever positive Phase 3 result for the vaccine program.
  • The excerpted coverage does not include the trial’s primary endpoint details, effect size, or safety findings.

Healthcare Related

Moderna shares surge more than 100% after report of a positive Phase 3 cancer vaccine result | The Apex Times